FDA Highlights Importance Of Computational Modeling
This article was originally published in The Gray Sheet
Executive Summary
During the Oct. 14 panel meeting, Bram Zuckerman, director of FDA’s Division of Cardiovascular Devices, emphasized the importance of computational modeling to further understand complex vascular regions like femoral arteries.
You may also be interested in...
CDRH Seeks To Increase Ranks Of Validated Computer Simulations
FDA’s device center says it wants to accelerate the evolution of physiological computer simulations from their current use as tools to tweak medical device designs to a future where they are fundamental components of a more streamlined device performance assessment.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.